

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Oct 2020 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Abiraterone	Zytiga	Malignant disease and immunosuppression	Approved	
2	Adalimumab	Amgevita	Musculoskeletal and joint disease	Approved	
3	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
4	Azithromycin eye drop	Azyter	Eye	Approved	
5	Celecoxib	Celebrex	Musculoskeletal and joint disease	Approved	
6	Dabrafenib / Trametinib	Tafinlar / Mekinist	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
7	Dasatinib	Sprycel	Malignant disease and immunosuppression	Approved	
8	Decitabine	Dacogen	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
9	Doravirine / lamivudine / tenofovir disoproxil fumarate	Delstrigo	Infections	Approved	
10	Emicizumab	Hemlibra	Cardiovascular system	Pending	Pending further information
11	Erenumab	Aimovig	Central nervous system	Approved	
12	Erlotinib	Erlotinib Sandoz	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
13	Liraglutide	Saxenda	Endocrine system	Pending	Pending further information
14	Neratinib	Nerlynx	Malignant disease and immunosuppression	Approved	
15	Octreotide LAR	Sandostatin LAR	Malignant disease and immunosuppression	Approved	
16	Olaparib	Lynparza	Malignant disease and immunosuppression	Approved	
17	Parecoxib	Dynastat	Musculoskeletal and joint disease	Approved	
18	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
19	Risankizumab	Skyrizi	Skin	Approved	
20	Semaglutide	Ozempic	Endocrine system	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
21	Tocilizumab	Actemra	Musculoskeletal and joint disease	Pending	Pending further information
22	Tofacitinib	Xeljanz	Musculoskeletal and joint disease	Approved	
23	Trastuzumab	Kanjinti	Malignant disease and immunosuppression	Approved	
24	Trastuzumab emtansine	Kadcyla	Malignant disease and immunosuppression	Approved	
25	Venetoclax	Venclexta	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.